Functional, cognitive and behavioural effects of 5-MeO-DMT administered by intramuscular injectio

Phase 1

• Conditions: Depression; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12623000884606
• Lead Sponsor: Swinburne University of Technology, Hawthorn

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-17
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Physically and mentally healthy.
Good command of the English language.
Prior experience with a psychedelic without experiencing adverse events.
Normal baseline ECG (determined by study medic).
Informed consent.
No psychedelic use within 2 weeks prior to the experiment.
Email access.
No anaemia.
Normal healthy body mass index (i.e., between 18.5-24.9).
Not use caffeine or nicotine 2 hours before or 6 hours after the dose.

Exclusion Criteria

Not physically and mentally healthy.
No command of the English language.
No prior experience with a psychedelic without experiencing adverse events.
Abnormal baseline ECG (determined by study medic).
No informed consent.
Psychedelic use within 2 weeks prior to the experiment.
No email access.
Anaemia.
Abnormal body mass index (i.e., below 18,5 or above 24,9).
Not use caffeine or nicotine 2 hours before or 6 hours after the dose.

Study & Design

• Study Type: Interventional
• Study Design: Not specified